AstraZeneca’s Savannah phase-II trial shows 49 per cent objective response in lung cancer…
MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targetted therapy
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.